TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5

被引：0
|
作者：
Prada, M. [1 ]
Berard, I [2 ]
Walzer, S. [3 ]
Darba, J. [4 ]
Greenwood, B. [5 ]
机构：
[1] Intexo, Rome, Italy
[2] NEXTEP, Paris, France
[3] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany
[4] Univ Barcelona, Barcelona, Spain
[5] Decideum, London W8 7JB, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1761
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY119
引用
收藏
页码：S264 / S264
页数：1
相关论文
共 50 条
  • [21] COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE
    Nientker, L.
    Trip, A. M.
    Hensen, M.
    VALUE IN HEALTH, 2019, 22 : S504 - S504
  • [22] TIMING OF EU5 & US ORPHAN DRUG APPROVALS AND PRMA BETWEEN 2009 AND 2013
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Pereira, E.
    Dellamano, L.
    Sagaydachnaya, O.
    Lue, J.
    VALUE IN HEALTH, 2015, 18 (03) : A305 - A305
  • [23] COMBINATION ONCOLOGY THERAPIES IN THE EU5: NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE IN MALIGNANT MELANOMA
    Privolnev, Y.
    Cox, J.
    Webster, R.
    VALUE IN HEALTH, 2018, 21 : S54 - S54
  • [24] WORTH THEIR WEIGHT? AN OVERVIEW OF THE INITIAL REIMBURSEMENT DECISIONS FOR GLP-1s IN THE EU5
    Tzaras, D.
    Macaulay, R.
    VALUE IN HEALTH, 2024, 27 (12) : S365 - S365
  • [25] ACCESS AND REIMBURSEMENT FOR CURRENT AND EMERGING ALZHEIMER'S DISEASE-MODIFYING THERAPIES IN THE EU5
    Privolnev, Y.
    Blutstein, T.
    Cox, J.
    Reyes, A.
    VALUE IN HEALTH, 2018, 21 : S344 - S344
  • [26] ASSESSING THE ACCEPTANCE OF POPULATION ADJUSTMENT METHODS IN ORPHAN DRUG HTA SUBMISSIONS IN THE EU5 AND THE NORDICS
    Kopsida, E.
    Tadic, I
    Lindblom, J.
    Medin, E.
    VALUE IN HEALTH, 2020, 23 : S706 - S706
  • [27] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [28] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [29] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [30] A PRICE COMPARISON STUDY OF RECENT DRUGS IN EU5, 2008-2012
    Le Pen, C.
    Vigier, D.
    Grandfils, N.
    VALUE IN HEALTH, 2013, 16 (07) : A455 - A455
12345